Jennifer Wilder
About
Jennifer Wilder is a scholar working on Hematology, Oncology and Genetics.
According to data from OpenAlex, Jennifer Wilder has authored 24 papers receiving a total of 159 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 9 papers in Oncology and 6 papers in Genetics. Recurrent topics in Jennifer Wilder's work include Hematopoietic Stem Cell Transplantation (19 papers), Virus-based gene therapy research (5 papers) and Renal Transplantation Outcomes and Treatments (5 papers). Jennifer Wilder is often cited by papers focused on Hematopoietic Stem Cell Transplantation (19 papers), Virus-based gene therapy research (5 papers) and Renal Transplantation Outcomes and Treatments (5 papers). Jennifer Wilder collaborates with scholars based in United States and Malaysia. Jennifer Wilder's co-authors include Roger Kurlander, Christa S. Zerbe, Amy P. Hsu, Juan Gea‐Banacloche, Katherine R. Calvo, Kenneth N. Olivier, Dennis D. Hickstein, Alexandra F. Freeman, Jennifer Cuellar‐Rodríguez and Steven M. Holland and has published in prestigious journals such as Blood, British Journal of Haematology and Transfusion.
In The Last Decade
Jennifer Wilder
21 papers receiving 157 citations
Peers
Jennifer Wilder
Kristen Cole United States
Florian Babor Germany
Bella Shadur Australia
Enrica Calzoni Italy
Д. С. Абрамов Russia
Gisele Loth Brazil
D H Fowler United States
Arno Rottal Austria
Citations per year, relative to Jennifer Wilder Jennifer Wilder (= 1×)
peers
Kristen Cole
Countries citing papers authored by Jennifer Wilder
Since
Specialization
Citations
This map shows the geographic impact of Jennifer Wilder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Wilder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Wilder more than expected).
Fields of papers citing papers by Jennifer Wilder
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jennifer Wilder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Wilder. The network helps show where Jennifer Wilder may publish in the future.
Co-authorship network of co-authors of Jennifer Wilder
This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Wilder. A scholar is included among the top collaborators of Jennifer Wilder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Wilder. Jennifer Wilder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Childs, Richard, Xin Tian, Georg Aue, et al.. (2025). REMOVED: Interim Results of a Phase II Trial of Omidubicel, Ex-Vivo Expanded Umbilical Cord Blood Transplantation in Patients with Treatment-Refractory Severe Aplastic Anemia. Transplantation and Cellular Therapy. 31(2). S41–S42.
2.
Holtzman, Noa G., Rachel B. Salit, Brian C. Shaffer, et al.. (2024). High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention. Blood Advances. 8(16). 4294–4310.
3.
Dimitrova, Dimana, Jennifer Wilder, Andrea Lisco, et al.. (2024). Safety but limited efficacy of donor lymphocyte infusion for post-transplantation cyclophosphamide-treated patients. Bone Marrow Transplantation. 59(11). 1513–1524.
4.
Dinh, Anh, Yihua Cai, Jennifer Wilder, et al.. (2023). Effects of extended transport on cryopreserved allogeneic hematopoietic progenitor cell (HPC ) product quality and optimal methods to assess HPC stability. Transfusion. 63(4). 774–781.
5.
Hamilton, Betty K., Corey Cutler, Clint Divine, et al.. (2022). Are We Making PROGRESS in Preventing Graft-versus-Host Disease and Improving Clinical Outcomes? Impact of BMT CTN 1301 Study Results on Clinical Practice. Transplantation and Cellular Therapy. 28(8). 419–425.
6.
Dimitrova, Dimana, Xingmin Feng, Francis A. Flomerfelt, et al.. (2022). Distally-Timed Equine Antithymocyte Globulin (eATG) in Allogeneic Hematopoietic Cell Transplantation (HCT) Conditioning – Pharmacokinetics and the Relationship between Total E-ATG Levels, Pre-HCT Absolute Lymphocyte Count, Immune Reconstitution, and Graft-Versus-Host Responses. Transplantation and Cellular Therapy. 28(3). S80–S80.
7.
Childs, Richard, Xin Tian, Enkhtsetseg Purev, et al.. (2021). Combined haploidentical and cord blood transplantation for refractory severe aplastic anaemia and hypoplastic myelodysplastic syndrome. British Journal of Haematology. 193(5). 951–960.
8.
Aue, Georg, Joseph Clara, Jennifer Wilder, et al.. (2020). Rapid Engraftment, Immune Recovery, and Resolution of Transfusion Dependence in Treatment-Refractory Severe Aplastic Anemia Following Transplantation with Ex Vivo Expanded Umbilical Cord Blood (Omidubicel). Blood. 136(Supplement 1). 37–38.
9.
Wilder, Jennifer, Sharon Adams, Joie Davis, et al.. (2019). Outcomes of Related and Unrelated Donor Searches Among Patients with Primary Immunodeficiency Diseases Referred for Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 25(8). 1666–1673.
10.
Wilder, Jennifer, A. John Barrett, Minoo Battiwalla, et al.. (2019). Incidence of Epstein-Barr Virus (EBV) Detection in the Blood, Pre-Emptive Therapy, and EBV-Posttransplantation Lymphoproliferative Disorder (EBV-PTLD) after Allogeneic Hematopoietic Cell Transplantation (HCT) across a Broad Range of HCT Approaches and All Graft Sources. Biology of Blood and Marrow Transplantation. 25(3). S353–S354.
11.
Childs, Richard, Georg Aue, Jennifer Wilder, et al.. (2018). Rapid Engraftment and Immune Recovery in Treatment Refractory Severe Aplastic Anemia Patients Undergoing Ex Vivo Nicotinamide-Expanded (NAM-Expanded) Unrelated Cord Blood Transplantation. Blood. 132(Supplement 1). 5789–5789.
12.
Kotecha, Ritesh R., Xin Tian, Jennifer Wilder, et al.. (2013). NK Cell KIR Ligand Mismatches Influence Engraftment Following Combined Haploidentical and Umbilical Cord Blood (UCB) Transplantation In Patients With Severe Aplastic Anemia (SAA). Blood. 122(21). 2038–2038.
13.
Salit, Rachel B., Frances T. Hakim, Michael R. Bishop, et al.. (2012). Influence of Graft Versus-Host Disease Prophylaxis Regimen On T-Cell Repertoire Diversity Following Reduced-Intensity HLA-Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation.. Blood. 120(21). 3054–3054.
14.
Gormley, Nicole, Jennifer Wilder, Jeremy Pantin, et al.. (2011). Co-Infusion of Allogeneic Cord Blood with Haploidentical CD34+ Cells Improved Transplant Outcome for Patients with Severe Aplastic Anemia Undergoing Cord Blood Transplantation. Blood. 118(21). 654–654.
15.
Kochenderfer, James N., Mark E. Dudley, I. Maric, et al.. (2011). Dramatic Regression of Chronic Lymphocytic Leukemia in the First Patient Treated With Donor-Derived Genetically-Engineered Anti-CD19-Chimeric-Antigen-Receptor-Expressing T Cells After Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 17(2). S158–S158.
16.
Kang, Elizabeth M., Corin Kelly, Dianne Hilligoss, et al.. (2011). A Novel Non Myeloablative Regimen for Related and Unrelated Allogeneic Transplantation of High Risk Patients With Chronic Granulomatous Disease (CGD). Biology of Blood and Marrow Transplantation. 17(2). S295–S295.
17.
Cuellar‐Rodríguez, Jennifer, Juan Gea‐Banacloche, Alexandra F. Freeman, et al.. (2011). Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Blood. 118(13). 3715–3720.
18.
Wilder, Jennifer, et al.. (2010). Bridging the Gap: 16 Years of Academic Leadership Development for Women. 3(1). 166–184.
19.
Salit, Rachel B., Steven Z. Pavletic, Daniel H. Fowler, et al.. (2010). Pilot Randomized Trial Comparing the Effects of Alemtuzumab and Cyclosporine Versus Tacrolimus, Methotrexate and Sirolimus on Graft Versus Host Disease Prevention, Engraftment and Immune Reconstitution After Reduced Intensity Unrelated Donor Transplantation.. Blood. 116(21). 1245–1245.
20.
Hsieh, Matthew M., et al.. (2007). Results of Alternative Donor Search in Adult Patients with Severe Sickle Cell Disease (SCD) Eligible for Hematopoietic Stem Cell Transplantation (HSCT).. Blood. 110(11). 2260–2260.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Kristen Cole Breakdown of academic impact, for papers by Venkateswaran Vellaichamy Swaminathan Breakdown of academic impact, for papers by Florian Babor Breakdown of academic impact, for papers by Bella Shadur Breakdown of academic impact, for papers by Enrica Calzoni Breakdown of academic impact, for papers by Д. С. Абрамов Breakdown of academic impact, for papers by Gisele Loth Breakdown of academic impact, for papers by D H Fowler Breakdown of academic impact, for papers by Arno Rottal